Washington (United States): Pharmaceutical giant Merck & Co Inc stated on Monday that it has applied for U.S. emergency use authorization for its experimental tablet to treat mild-to-moderate patients of COVID-19, making it the first oral antiviral medication for the disease. An authorization from the U.S. Food and Drug Administration could help change clinical management of COVID-19 globally as the pill can be taken at home.
This comes after the phase three clinical trial data released on October 1 that showed the medication ‘molnupiravir’ reduced the chances that patients newly diagnosed with Covid would be hospitalized by about 50%.
“The extraordinary impact of this pandemic demands that we move with unprecedented urgency, and that is what our teams have done by submitting this application for molnupiravir to the FDA within 10 days of receiving the data,” Merck CEO Robert Davis said in a press release.
The pill is expected to be available in America later this year. Merck further added that it is actively working with regulatory agencies worldwide to submit applications for emergency use or authorization “in the coming months.”